Eli Lilly Expands Its In Vivo Ambitions, Acquiring Cell Therapy Startup Orna for up to $2.4B – MedCity News
The next frontier for cell therapy is shaping up to be in vivo treatments for autoimmune disease, and Eli Lilly…
The next frontier for cell therapy is shaping up to be in vivo treatments for autoimmune disease, and Eli Lilly…